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Abstract. 
Background. 
The Drug Burden Index (DBI) calculates the total sedative and anticholinergic load of prescribed 
medications, and is associated with functional decline and hip fractures in older adults. However, 
it is unknown if confounding factors influence the relationship between the DBI and hip fractures. 
The objective of this study is to evaluate the association between the DBI and hip fractures, after 
correcting for mortality and multiple potential confounding factors. 
Methods. 
A competing risk regression analysis conducted on a prospectively recruited New Zealand 
community-dwelling older population who had a standardized (interRAI) assessment between 1 
September 2012 and 31 October 2015, the study’s end date. Outcome measures were survival 
status, and hip fracture, with time-varying DBI exposure derived from 90-day time-intervals. The 
multivariable competing risk regression model adjusted for a large number of medical 
comorbidities and activities of daily living. 
Results. 
Among 70,553 adults assessed, 2,249 (3.2%) experienced at least one hip fracture, 20,194 (28.6%) 
died without experiencing a fracture, and 48,110 (68.2%) survived without a fracture. The mean 
follow-up time was 14.9 months (range: 1 day, 37.9 months).  The overall DBI distribution was 
highly skewed, with median time-varying DBI exposure ranging from 0.93 (Q1=0.0, Q3=1.84) to 
0.96 (Q1=0.0, Q3=1.90). DBI was significantly related to fracture incidence in unadjusted 
(p<0.001) and adjusted (p<0.001) analyses. The estimated subhazard ratio was 1.52 (95% 
confidence interval: 1.28, 1.81) for those with DBI>3 compared with those with DBI=0 in the 
adjusted analysis.  
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Conclusions. 
In this study, increasing DBI was associated with a higher likelihood of fractures after accounting 
for the competing risk of mortality and adjusting for confounders. The results of this unique study 
are important in validating the DBI as a guide for medication management and it could help reduce 
the risk of hip fractures in older adults. 
Key words. Polypharmacy, medications, RAI, falls 
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Introduction. 
Hip fractures in frail older people often require complex care and may lead to loss of 
independence. After hip fractures, older people often require aged residential care, which is 
costly to the patient and the health system.(1) Twenty to thirty percent of older people with hip 
fractures die within 12 months of their injury.(2) If surgery is undertaken, patients frequently 
experience significantly reduced hip function and mobility beyond 12 months.(3) Approximately 
90% of hip fractures in older people are a direct result of a fall,(4) consequently clinicians must 
prioritize initiatives that help reduce the risk of falls and subsequent hip fractures in older people.  
Polypharmacy can increase the risk of falls in older people.(5) Research has highlighted that 
medications with sedative and anticholinergic properties significantly increase the risk of falls in 
the older populations.(6) While there are many benefits of modern pharmacological 
interventions,(7) and polypharmacy may at times be entirely appropriate, deprescribing, 
particularly the withdrawal of some sedative and anticholinergic drugs may result in clinical 
benefit for some individuals, such as an improvement in physical function.(6,8,9) 
The Drug Burden Index (DBI) was developed as a pharmacological risk assessment tool.(10) 
Unlike other tools that identify potentially inappropriate medication use,(11,12) the DBI 
calculates the cumulative sedative and anticholinergic load of an individual’s prescribed 
medications.(13) Previous work has highlighted the relationship between a high DBI score and 
functional decline in older populations, and falls and fractures.(6,9,14,15) Nonetheless, the 
association of the DBI with hip fractures has not yet been explored at a population level. 
Our national study examined the relationship between DBI and hip fractures in the frail elderly 
after adjusting for multiple possible confounders within the New Zealand International Resident 
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Assessment Instrument (interRAI) dataset. We linked pharmaceutical, mortality and fracture data 
with anonymized interRAI-Home Care data (interRAI-HC).  
 
METHODS 
We conducted a competing-risk regression analysis on a prospectively recruited national cohort. 
 
Participants 
The participants included home-based people aged 65 years and older who had an interRAI-
homecare (HC) assessment between 1 September 2012 and 31 October 2015, the study’s end date, 
and who consented to their data being used for planning and research purposes. In New Zealand, 
the interRAI-HC instrument is used for all community care assessments of older people being 
considered for publicly-funded long-term community services or aged residential care in New 
Zealand.(16)  
 
Procedure 
A detailed account of the interRAI-HC assessment instrument and procedure within New Zealand 
has been described previously.(16) In brief, the standardized interRAI-HC instrument is used to 
conduct all community care assessments on older people needing publicly funded long-term 
community services or aged residential care. Individuals are referred by a health practitioner to 
have their needs assessed by one of the 1,800+ trained interRAI assessors. Assessors visit clients 
in their own home to produce individualized care-plans according to a standardized protocol. 
Participants are explicitly asked if they consent to their de-identified interRAI-HC information 
being used for planning and research purposes. All data are directly entered into an electronic 
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interRAI-HC database that is maintained by New Zealand’s Technical Advisory Services (TAS; 
http://centraltas.co.nz). With approval consented data are released by TAS through the Ministry of 
Health. 
 
Instrument and primary measures 
The interRAI-HC 9.1 instrument (© interRAI Corporation, Washington, D.C., 1994-2009), 
modified with permission for New Zealand, is used under license to the New Zealand Ministry of 
Health (www.interrai.co.nz). It is composed of 236 questions, which form 27 standardized 
instruments, and yields internationally valid and reliable scales.(16,17) InterRAI-HC information 
is stored electronically and is linked to the National Health Index (NHI) numbers using encryption 
for data security. The NHI is a unique identifier that is assigned to every person who uses health 
and disability support services in New Zealand. 
The fracture data were extracted from the Ministry of Health’s National Minimum Dataset 
(NMDS),(18) released with encrypted NHI numbers for all consenting interRAI-HC participants. 
Fractures included: ICD-10-AM codes S720 – fracture of head and neck of femur; S721 – 
pertrochanteric fracture; S722 – subtrochanteric fracture of femur; S723 – fracture of shaft of 
femur; S724 – fracture of lower end of femur; S728 – other fracture of femur; and S729 – 
unspecified fracture of femur. Only the first documented fracture and date of that fracture were 
used in the study.  
Survival status and date of death data were extracted from the National Mortality Collection 
Register (NMCR), also held by the Ministry of Health,(19) and released with encrypted NHI 
numbers for all consenting interRAI-HC participants.  
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Pharmaceutical information, including medicine names and prescription dates, were captured by 
the national collections of prescription use (Pharmaceutical Collection), jointly owned by the 
Ministry of Health and PHARMAC, and linked through encrypted NHI numbers. The Drug 
Burden Index (DBI) exposure was calculated for medicines with anticholinergic and sedative 
properties (see Table S1 in the supplementary materials) dispensed from 1 September 2011 
through 31 October 2015.  The drug burden attributable to each anticholinergic or sedative 
medicine was calculated using the equation: 
  Drug Burden Index = ∑ 𝐷/ (𝐷 +  𝛿)
90
0
 
where D is the daily supply (or dose) taken by the individual and δ is the minimum efficacious 
dose. As pharmaceutical prescribing changes over time, each participant’s DBI exposure was 
treated as a time varying variable, partitioned into 90-day intervals over their study duration, 
beginning with the 90 days pre-interRAI-HC assessment. The cumulative DBI exposure for each 
90-day interval was calculated using the principles trapezoidal area under the curve as described 
in the original study (20). Area under the curve for drug burden was derived by calculating the 
drug burden index for each drug multiplied by the time of exposure (90 days). It was assumed that 
any medicines dispensed during the 90-day period were taken for the full 90 days.  Dispensing for 
more than 90 days was truncated to 90 days. The DBI was then partitioned into four groups, 
namely: (i) DBI=0; (ii) 0<DBI≤1; (iii) 1<DBI≤3; and, (iv) DBI>3. DBI=0 is the most numerous 
and covers participants who do not take the anticholinergic and sedative drugs. In smaller studies, 
DBI=1 is often used as a threshold value. But here, with a large sample, DBI=3 captures the most 
extreme drug burdens among participants. These thresholds have both clinical and statistical 
utility, as demonstrated previously. (14) 
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Demographic and potentially confounding measures 
Similar to previous published studies, age, sex, ethnicity, body mass index (BMI), cognitive 
performance, dementia, congestive heart failure (CHF), chronic obstructive pulmonary disease 
(COPD), depression, diabetes mellitus, urinary incontinence, alcohol consumption, smoking 
status, hearing status, vision status, fatigue, mobility, wandering, seasonality, and supplementation 
of bisphosphonates, vitamin D, and calcium were all utilized as potential confounding factors. 
Apart from the supplementations, all measures arose from the interRAI-HC assessment. The 
bisphosphonates, vitamin D, and calcium supplementation indications were also derived from the 
Pharmaceutical Collection and were treated as time varying confounders, as was season, over 90-
day intervals. All variable specification details appear in the supplementary materials Table S2. 
 
Statistical analysis 
Reporting of analyses were informed by the STrengthening the Reporting of OBservational studies 
in Epidemiology (STROBE) guidelines (www.strobe-statement.org). The interRAI-HC, NMDS, 
and NMCR databases were deterministically matched using participants’ encrypted NHI numbers. 
Where an individual had more than one interRAI-HC assessment, only the first assessment was 
utilized. Several interRAI-HC variables were re-classified, as given in the supplementary material, 
with contiguous categories combined when cell sizes were relatively small. Descriptive statistics 
of all variables of interest were then reported. Competing risk regression models were next 
employed, treating fracture as the primary event of interest and death as a competing event.  
Initially unadjusted models were investigated, followed by a multivariable model with inclusion 
of demographic and potential confounding variables. Exploring whether a differential influence of 
sex and age might have on the relationship between DBI grouping and fracture likelihood, the 
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multivariable competing risk regression model was repeated with the addition of DBI 
grouping×sex and DBI grouping×age grouping interaction terms. Rather than using bivariable 
analyses to screen risk factors, in the spirit of Sun and colleagues,(21) all candidate variables were 
included in the multivariable model regardless of their statistical significance. Subhazard ratios 
(SHRs) and associated 95% confidence intervals (CIs) were reported, and Wald’s type III χ2 test 
was used to determine the significance of variables within the regression. The population 
attributable fraction (PAF) was used to estimate the proportional reduction in fracture numbers 
that would occur if exposure to DBI at baseline was reduced to an alternative ideal exposure 
scenario (DBI=0), and 95% CIs derived using computer simulation.(22) All analyses and graphics 
were performed using Stata SE version 14.1 (StataCorp, College Station, TX, USA), and α=0.05 
defined statistical significance. 
 
Table S3 in the supplementary materials gives the observed distribution and regression estimates 
for the unadjusted and multivariable models for all considered variables. Exploring whether a 
differential influence of sex and age might have on the relationship between DBI grouping and 
fracture likelihood, the multivariable competing risk regression model was repeated except with 
the addition of DBI grouping×sex and DBI grouping×age grouping interaction terms. 
 
Ethics 
Clearance for this study was approved by the Ministry of Health’s Health and Disability Ethics 
Committees (14/STH/140), and it only includes de-identified data for people consenting to its use 
for planning and research purposes. 
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RESULTS 
The study cohort included 72,193 individuals aged ≥65 years (Figure 1). After exclusions, there 
were 70,553 eligible individuals. The average age at assessment was 82.7 years (range: 65, 106 
years; Table 1). Approximately two-thirds of those assessed were female with a higher proportion 
of females than males alive at the end of the study period. Most people (88.5%) were New Zealand 
European and approximately half the individuals were living alone. The average follow-up time 
was 14.9 months after the interRAI assessment (range: 1 day, 37.9 months), totaling 87,671 
person-years of follow-up data. 
 
Fractures and mortality 
By the study end-date, 2,249 (3.2%) participants had experienced at least one fracture, 20,194 
(28.6%) had died without experiencing a fracture, and 48,110 (68.2%) were alive and without a 
fracture (Figure 1). The median time from assessment to the first fracture event was 8.5 months 
(Q1=3.7, Q3=15.5 months), and from assessment to death (without fracture) was 6.9 months 
(Q1=2.2, Q3=15.0 months). Table 1 also includes the demographic profile of participants by facture 
status, and shows important distributional differences. Fracture rates increased with increasing age, 
females had relatively higher rates than males, New Zealand Europeans had relatively higher rates 
than other ethnic classifications, as did participants who were widowed, or who lived alone or with 
a child (but not a spouse or partner).  
 
Drug Burden Index (DBI)  
The distribution DBI values was highly skewed (see Figure 2). In the pre-assessment 90-day 
period, 29,111 (41.3%) participants had a DBI equaling 0; taking no medications that contributed 
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to the index, 20,791 (29.5%) had 0<DBI≤1; 16,600 (23.5%) had 1<DBI≤3; and, 4,051 (5.7%) had 
DBI>3. The numbers of participants available within the study at baseline and at time-points after 
baseline, together with the median (Q1, Q3) DBI exposure score of these participants is presented 
in Table 2. Median DBI scores remained low throughout the study period. The correlation in DBI 
scores between contiguous 90-day intervals ranged from 0.68 (between pre- and 0-89 days post-
assessment DBI scores) to 0.85 (between 900-989 days and 990-1079 days post-assessment DBI 
scores) meaning subjects experienced a relatively constant rate of anti-cholinergic drug use over 
time. 
 
Unadjusted analyses 
Treating DBI as a time-varying variable, the unadjusted competing-risk regression model yielded 
a significant relationship between DBI grouping and fractures over time (p<0.001), with estimated 
subhazard ratios (SHRs) and associated 95% CIs presented in Table 3. There appeared to be a 
dose-response relationship between estimated SHRs, with increasing drug burden associated with 
a higher likelihood of fractures, after accounting for the competing increasing death rate. Figure 
3a gives the cumulative incidence of fractures over time by DBI groupings from this analysis. 
 
Adjusted analyses 
After multivariable adjustment, the DBI grouping remained significantly related to fracture 
incidence (p<0.001) (Table 3). Table S3 in the supplementary materials gives the observed 
distribution and regression estimates for the bivariable and multivariable models for all considered 
variables. The apparent dose-response relationship between DBI grouping and facture incidence 
observed in the unadjusted analysis remained in the multivariable analysis; indeed, it appeared 
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stronger than in the unadjusted model. Figure 3b, which also depicts the cumulative incidence of 
fractures over time by DBI groupings visually highlights the strength of this association. Note, in 
this graphic all included demographic and potential confounder variables were assigned their 
reference values (as given in Tables 3 and S3 of the supplementary materials). However, no 
evidence of DBI grouping effect modification was seen by sex (p=0.53) or age grouping (p=0.42). 
 
Population attributable fraction 
The population attributable fraction (PAF) derived from the adjusted subhazard estimates and the 
observed baseline DBI distribution (Table 3), assuming a counterfactual population level of 
DBI=0, yielded PAF=12.3% (95% CI: 8.2%, 61.1%).  
 
Discussion 
In this national study, higher DBI scores were associated with an increased likelihood of hip 
fractures after accounting for the competing risk of mortality. This is consistent with previous 
observations of the association of DBI with falls in the total New Zealand population aged over 65 
years, (9) and in residents of Australian aged care facilities.(15) It is also consistent with the large 
body of evidence demonstrating an association between different types of drugs with 
anticholinergic and sedative effects and falls and fractures.   
A strength of this study was that after adjusting for a suite of potential confounders, the dose 
response relationship between DBI scores and fractures increased. Unlike most studies that have 
demonstrated an association between DBI and adverse outcomes at a population level, (20, 23,24) 
this study controlled for a wide range of potential confounders including  baseline function and 
medical comorbidities.    
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A number of studies support the validity of the DBI as an aid to prescribing.(6,9,10) One reported 
a relationship between falls and fractures and specific medication groups such as psychotropic 
drugs.(15) Another study investigated the association between the DBI and physical function in a 
population of aged residential care residents in Australia.(15)That cohort’s mean age was slightly 
greater than our community based study. In that study, sedative exposure was significantly 
associated with poor balance (OR 1.57, 95% CI 1.08-2.27), a known risk factor for falls in older 
populations.(15) Poorer physical function has also been reported associated with the increased use 
of sedative and anticholinergic medications as defined by the DBI rather than polypharmacy per 
se.(13) An important association between both long and short acting benzodiazepines and falls 
was found in a study of older people living in long-term residential care, although the cumulative 
effect of other sedative and anticholinergic medications was not considered.(25) Other reported 
research has also highlighted the link between narcotic analgesics and risk of fractures,(26) and 
the association between SSRI use and falls and hip fractures in the older populations.(27-30) 
Reducing polypharmacy and identifying at risk medications is generally important. Up to 50% of 
older people have exposure to medications with anticholinergic properties.(31) These data indicate 
that the total anticholinergic and sedative load should be considered particularly in the context of 
reducing fractures rates in the frail older population. 
Ours is the first study to examine the relationship between hip fractures in older people and the 
DBI at a population level. The rich source of data made available through the interRAI-HC data 
base in New Zealand, linked to pharmaceutical, fracture and mortality data allowed us to include 
confounders that have previously been unavailable to other population based studies of the most 
frail and vulnerable older people.(16,32)  
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Limitations 
The New Zealand interRAI-HC identifies older people who are most frail and vulnerable and who 
are therefore most likely to be at risk of falls and fractures. We acknowledge, also, that in our study 
the period between individual interRAI-HC assessments and any subsequent fracture varied 
between participants, and so any variance in Activities of Daily Living (ADL) function or 
cognition may not always have been captured. Although all dispensed medications in the study 
period were utilized, there was no way of ascertaining whether they had always been consumed. 
Furthermore, non-prescription medications with anticholinergic and sedative effects, such as some 
antihistamines and mild opioids, were not captured by our data sets, so could not be included in 
the DBI calculations. We adjusted for many potential important confounders including congestive 
heart failure; however, we did not have detailed information on every potential confounder, such 
as musculoskeletal pain, and it is possible that residual confounding remains. The interRAI-HC 
assessment involves a significant degree of self-reporting, which may result in some 
inconsistencies, for example when the individual has a degree of cognitive impairment. However, 
assessments are often completed in the company of a spouse or other family member and primary 
care doctors are consulted to verify the information provided and clarify unclear details. It is 
important to note that the absolute DBI exposure may be higher in longitudinal studies compared 
to cross sectional studies because we calculate cumulative (multiplied by time) drug exposure in 
longitudinal studies. As shown in this study, higher exposures are associated with worse clinical 
outcomes, but we could not extrapolate information on the cut-offs or degree of DBI exposure. 
Misclassification of drug exposure is inherent in pharmacoepidemiological studies, and in this 
study it was difficult to discern regular versus prn medications from dispensed data extracted from 
the national pharmaceutical collections. 
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Conclusion 
This national study demonstrated that increasing exposure to anticholinergic and sedative 
medications is significantly associated with hip fractures in frail community dwelling older 
people in New Zealand.  The Drug Burden Index may be useful as a risk assessment tool, 
helping clinicians to review prescribing for older patients.  Exposure to anticholinergic and 
sedative medicines is a potentially reversible contributor to hip fractures, which cause significant 
morbidity and mortality for older people, and major costs of the health and aged care services.  
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Table 1. Demographics of eligible participants overall (n=70,553), and partitioned by outcome.  
   Alive, no fracture First event 
  Total by end-date Fracture Died 
  n n (%) n (%) n (%) 
Age (years)        
 65-74 12,175 9,124 (74.9) 174 (1.4) 2,877 (23.6) 
 75-84 28,999 20,656 (71.2) 820 (2.8) 7,523 (25.9) 
 85-94 27,048 17,131 (63.3) 1,120 (4.1) 8,797 (32.5) 
 95+ 2,331 1,199 (51.4) 135 (5.8) 997 (42.8) 
Sexa        
 Female 43,048 30,945 (71.9) 1,569 (3.6) 10,534 (24.5) 
 Male 27,501 17,162 (62.4) 680 (2.5) 9,659 (35.1) 
Ethnicity        
 European 62,436 42,257 (67.7) 2,134 (3.4) 18,045 (28.9) 
 Māori 3,814 2,638 (69.2) 41 (1.1) 1,135 (29.8) 
 Pacific 2,187 1,622 (74.2) 26 (1.2) 539 (24.6) 
 Other 2,116 1,593 (75.3) 48 (2.3) 475 (22.4) 
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Marital status        
 Married/civil union/de 
facto 
27,400 18,520 (67.6) 771 (2.8) 8,109 (29.6) 
 Widowed 34,194 23,292 (68.1) 1,258 (3.7) 9,644 (28.2) 
 Divorced/separated 5,144 3,685 (71.6) 133 (2.6) 1,326 (25.8) 
 Never married 3,235 2,235 (69.1) 71 (2.2) 929 (28.7) 
 Other 580 378 (65.2) 16 (2.8) 186 (32.1) 
Residential arrangements: living withb       
 Spouse/partner only 22,343 15,086 (67.5) 621 (2.8) 6,636 (29.7) 
 Spouse/partner and other(s) 2,396 1,598 (66.7) 60 (2.5) 738 (30.8) 
 Alone 34,973 24,334 (69.6) 1,215 (3.5) 9,424 (26.9) 
 Child (not spouse/partner) 7,676 4,992 (65.0) 263 (3.4) 2,421 (31.5) 
 Other relative(s) 1,729 1,184 (68.5) 49 (2.8) 496 (28.7) 
 Non-relative(s) 1,434 915 (63.8) 41 (2.9) 478 (33.3) 
Note: a4 observations missing; b2 observations missing. See Table S3 of the Supplementary 
materials for details of demographic and potentially confounding variables by outcome at the 
study’s end date. 
  
24 
 
Table 2. Numbers of people remaining at risk of hip fracture and/or death and their median (Q1, Q3) 
DBI exposure score. 
Time after   DBI exposure 
assessment 
(days) 
n (%) mediana (Q1, Q3) 
Baseline 70,553 (100.0) 0.93 (0.0, 1.81) 
90 59,192 (83.9) 0.94 (0.0, 1.83) 
180 51,303 (72.7) 0.93 (0.0, 1.81) 
270 44,669 (63.3) 0.93 (0.0, 1.81) 
360 39,090 (55.4) 0.93 (0.0, 1.82) 
450 33,280 (47.2) 0.93 (0.0, 1.83) 
540 27,384 (38.8) 0.93 (0.0, 1.84) 
630 22,129 (31.4) 0.93 (0.0, 1.84) 
720 17,429 (24.7) 0.94 (0.0, 1.85) 
810 12,162 (17.2) 0.94 (0.0, 1.86) 
900 7,649 (10.8) 0.94 (0.0, 1.87) 
990 4,351 (6.2) 0.95 (0.0, 1.90) 
1,080 1,871 (2.7) 0.96 (0.0, 1.90) 
aDBI values measured over time 
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Table 3. Distribution of DBI groupings for the pre-assessment period by outcome at the study’s end date, together with subhazard ratios (SHRs) 
and 95% confidence intervals (CIs) for the unadjusted and adjusted analyses. 
 Alive, no fracture First event   
 by end-date Fracture Died Unadjusted Adjusteda 
 n (%) n (%) n (%) SHR (95% CI) SHR (95% CI) 
DBI=0 20,274 (69.6) 893 (3.1) 7,944 (27.3) 1 (reference) 1 (reference) 
0<DBI≤1 14,306 (68.8) 687 (3.3) 5,798 (27.9) 1.11 (1.00, 1.23) 1.12 (1.01, 1.24) 
1<DBI≤3 11,051 (66.6) 544 (3.3) 5,005 (30.2) 1.24 (1.12, 1.38) 1.32 (1.18, 1.47) 
3<DBI 2,479 (61.2) 125 (3.1) 1,447 (35.7) 1.28 (1.08, 1.52) 1.52 (1.28, 1.81) 
aAdjusted for: age, sex, ethnicity, body mass index (BMI), cognitive performance, dementia, congestive heart failure (CHF), chronic 
obstructive pulmonary disease (COPD), depression, diabetes mellitus, urinary incontinence, alcohol consumption, smoking status, 
hearing status, vision status, fatigue, mobility, wandering, seasonality, and supplementation of bisphosphonates, vitamin D, and calcium
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